Tags

Type your tag names separated by a space and hit enter

Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
Phytomedicine. 2021 Jul; 87:153591.P

Abstract

BACKGROUND

The outbreak of coronavirus (SARS-CoV-2) disease caused more than 100,000,000 people get infected and over 2,200,000 people being killed worldwide. However, the current developed vaccines or drugs may be not effective in preventing the pandemic of COVID-19 due to the mutations of coronavirus and the severe side effects of the newly developed vaccines. Chinese herbal medicines and their active components play important antiviral activities. Corilagin exhibited antiviral effect on human immunodeficiency virus (HIV), hepatitis C virus (HCV) and Epstein-Barr virus (EBV). However, whether it blocks the interaction between SARS-CoV-2 RBD and hACE2 has not been elucidated.

PURPOSE

To characterize an active compound, corilagin derived from Phyllanthus urinaria as potential SARS-CoV-2 entry inhibitors for its possible preventive application in daily anti-virus hygienic products.

METHODS

Computational docking coupled with bio-layer interferometry, BLI were adopted to screen more than 1800 natural compounds for the identification of SARS-CoV-2 spike-RBD inhibitors. Corilagin was confirmed to have a strong binding affinity with SARS-CoV-2-RBD or human ACE2 (hACE2) protein by the BLI, ELISA and immunocytochemistry (ICC) assay. Furthermore, the inhibitory effect of viral infection of corilagin was assessed by in vitro pseudovirus system. Finally, the toxicity of corilagin was examined by using MTT assay and maximal tolerated dose (MTD) studies in C57BL/6 mice.

RESULTS

Corilagin preferentially binds to a pocket that contains residues Cys 336 to Phe 374 of spike-RBD with a relatively low binding energy of -9.4 kcal/mol. BLI assay further confirmed that corilagin exhibits a relatively strong binding affinity to SARS-CoV-2-RBD and hACE2 protein. In addition, corilagin dose-dependently blocks SARS-CoV-2-RBD binding and abolishes the infectious property of RBD-pseudotyped lentivirus in hACE2 overexpressing HEK293 cells, which mimicked the entry of SARS-CoV-2 virus in human host cells. Finally, in vivo studies revealed that up to 300 mg/kg/day of corilagin was safe in C57BL/6 mice. Our findings suggest that corilagin could be a safe and potential antiviral agent against the COVID-19 acting through the blockade of the fusion of SARS-CoV-2 spike-RBD to hACE2 receptors.

CONCLUSION

Corilagin could be considered as a safe and environmental friendly anti-SARS-CoV-2 agent for its potential preventive application in daily anti-virus hygienic products.

Authors+Show Affiliations

Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China.Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China.Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China; Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan.School of Pharmacy, Macau University of Science and Technology, Macau, China.Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China.Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China.Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, Guangdong, 528000, China.Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medical University, Foshan, Guangdong, 528000, China.Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China. Electronic address: yklaw@must.edu.mo.Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China. Electronic address: bowaiwong@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34029937

Citation

Yang, Li Jun, et al. "Corilagin Prevents SARS-CoV-2 Infection By Targeting RBD-ACE2 Binding." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 87, 2021, p. 153591.
Yang LJ, Chen RH, Hamdoun S, et al. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Phytomedicine. 2021;87:153591.
Yang, L. J., Chen, R. H., Hamdoun, S., Coghi, P., Ng, J. P. L., Zhang, D. W., Guo, X., Xia, C., Law, B. Y. K., & Wong, V. K. W. (2021). Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 87, 153591. https://doi.org/10.1016/j.phymed.2021.153591
Yang LJ, et al. Corilagin Prevents SARS-CoV-2 Infection By Targeting RBD-ACE2 Binding. Phytomedicine. 2021;87:153591. PubMed PMID: 34029937.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. AU - Yang,Li Jun, AU - Chen,Rui Hong, AU - Hamdoun,Sami, AU - Coghi,Paolo, AU - Ng,Jerome P L, AU - Zhang,David Wei, AU - Guo,Xiaoling, AU - Xia,Chenglai, AU - Law,Betty Yuen Kwan, AU - Wong,Vincent Kam Wai, Y1 - 2021/05/05/ PY - 2021/02/26/received PY - 2021/04/27/revised PY - 2021/04/29/accepted PY - 2021/5/25/pubmed PY - 2021/7/7/medline PY - 2021/5/24/entrez KW - COVID-19 KW - Corilagin KW - RBD-ACE2 inhibitor KW - SARS-CoV-2 KW - Viral infection SP - 153591 EP - 153591 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 87 N2 - BACKGROUND: The outbreak of coronavirus (SARS-CoV-2) disease caused more than 100,000,000 people get infected and over 2,200,000 people being killed worldwide. However, the current developed vaccines or drugs may be not effective in preventing the pandemic of COVID-19 due to the mutations of coronavirus and the severe side effects of the newly developed vaccines. Chinese herbal medicines and their active components play important antiviral activities. Corilagin exhibited antiviral effect on human immunodeficiency virus (HIV), hepatitis C virus (HCV) and Epstein-Barr virus (EBV). However, whether it blocks the interaction between SARS-CoV-2 RBD and hACE2 has not been elucidated. PURPOSE: To characterize an active compound, corilagin derived from Phyllanthus urinaria as potential SARS-CoV-2 entry inhibitors for its possible preventive application in daily anti-virus hygienic products. METHODS: Computational docking coupled with bio-layer interferometry, BLI were adopted to screen more than 1800 natural compounds for the identification of SARS-CoV-2 spike-RBD inhibitors. Corilagin was confirmed to have a strong binding affinity with SARS-CoV-2-RBD or human ACE2 (hACE2) protein by the BLI, ELISA and immunocytochemistry (ICC) assay. Furthermore, the inhibitory effect of viral infection of corilagin was assessed by in vitro pseudovirus system. Finally, the toxicity of corilagin was examined by using MTT assay and maximal tolerated dose (MTD) studies in C57BL/6 mice. RESULTS: Corilagin preferentially binds to a pocket that contains residues Cys 336 to Phe 374 of spike-RBD with a relatively low binding energy of -9.4 kcal/mol. BLI assay further confirmed that corilagin exhibits a relatively strong binding affinity to SARS-CoV-2-RBD and hACE2 protein. In addition, corilagin dose-dependently blocks SARS-CoV-2-RBD binding and abolishes the infectious property of RBD-pseudotyped lentivirus in hACE2 overexpressing HEK293 cells, which mimicked the entry of SARS-CoV-2 virus in human host cells. Finally, in vivo studies revealed that up to 300 mg/kg/day of corilagin was safe in C57BL/6 mice. Our findings suggest that corilagin could be a safe and potential antiviral agent against the COVID-19 acting through the blockade of the fusion of SARS-CoV-2 spike-RBD to hACE2 receptors. CONCLUSION: Corilagin could be considered as a safe and environmental friendly anti-SARS-CoV-2 agent for its potential preventive application in daily anti-virus hygienic products. SN - 1618-095X UR - https://www.unboundmedicine.com/medline/citation/34029937/Corilagin_prevents_SARS_CoV_2_infection_by_targeting_RBD_ACE2_binding_ DB - PRIME DP - Unbound Medicine ER -